return 5% to 30% of the time following initial treatment, said lead researcher Dr. Paolo Tarantino, also with Dana-Farber.helps inhibit HER2-positive cancers by blocking that protein. When given alongside chemotcan significantly reduce the risk cancer will recur in these patients, Tarantino said.Kadcyla is a single drug that combines trastuzumab with thedrug emtansine. It was developed to provide the benefits of chemotherapy and immunotherapy while limiting toxic side effects.
For the new clinical trial, researchers recruited 512 patients at cancer centers across the United States, with 384 receiving Kadcyla and 128 treated with chemoFive years after treatment, 97% of patients who got Kadcyla had no evidence of cancer recurrence. The rate of toxic side effects were similar between the two groups, but patient-reported outcomes showed better quality of life with Kadcyla, researchers said.and better work productivity with Kadcyla than with chemo and trastuzumab given separately.The results were published June 27 in the
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: Medscape - 🏆 386. / 55 Read more »